You are here: Industry Insights > Orkambi

News List

The price of access: Can the NHS afford Orkambi? pharmafile
May 09, 2019
The price of access: Can the NHS afford Orkambi?
NHS England calls Vertex an ‘extreme outlier’ in conduct of Orkambi negotiations pharmaceutical-technology
March 08, 2019
During a House of Commons Health and Social Care Committee witness session on the availability of Vertex’s Orkambi and other cystic fibrosis (CF) drugs on the National Health Service (NHS)
UK politicians to grill Vertex CEO over CF price drug row pharmaphorum
March 07, 2019
The CEO of Vertex Pharmaceuticals is to give evidence before influential UK politicians on Thursday, who are investigating the ongoing row over the price of cystic fibrosis drugs in England.
EC approves Vertex’s Orkambi for children with cystic fibrosis pharmaceutical-technology
January 23, 2019
Vertex Pharmaceuticals has received approval from the European Commission (EC) to expand the indication of its Orkambi to treat paediatric patients suffering from cystic fibrosis (CF)....
EU label for Vertex's cystic fibrosis drug Orkambi expanded again to include even younger children firstwordpharma
January 22, 2019
Orkambi was initially approved in Europe in 2015 for patients with CF ages 12 years and older who have two copies of the F508del mutation and was later expanded to include children ages six to 11 years.
EU label for Vertex's cystic fibrosis drug Orkambi expanded again to include even younger children firstwordpharma
January 22, 2019
Orkambi was initially approved in Europe in 2015 for patients with CF ages 12 years and older who have two copies of the F508del mutation and was later expanded to include children ages six to 11 years.
Scotland’s NHS could reimburse Vertex CF drugs, price row ongoing in England pharmaphorum
December 21, 2018
Vertex is to file its two latest cystic fibrosis drugs with Scotland’s drug cost watchdog in a bid for NHS reimbursement – but an ongoing row over price in England is still unresolved.
Vertex to submit Orkambi, Symkevi to SMC pharmatimes
December 21, 2018
Vertex has revealed that it will be submitting its cystic fibrosis medicines Orkambi and Symkevi to the Scottish Medicines Consortium for appraisal, following “constructive discussions” with the Scottish government.
Vertex told to reveal CF drug price, as MPs begin inquiry pharmaphorum
December 04, 2018
UK politicians could go public with the price of Vertex’s cystic fibrosis drug Orkambi, if the company does not strike a deal giving NHS patients access by the end of the month.
Vertex’s cystic fibrosis drugs become publicly available in Denmark pharmaceutical
November 19, 2018
Vertex Pharmaceuticals has signed an access agreement with Denmark’s pharmaceutical procurement agency Amgros for public hospital use of all current and future drugs for mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Previous page 1 2 Next page